TNTobi E. Nagel

Tobi E. Nagel

*This is an algorithmically generated author record based on publicly available information.

Tobi E. Nagel has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Angela Makumi

    International Livestock Research Institute (ILRI), P.O. Box 30709, Nairobi 00100, Kenya

    1 shared publication
  • Annette Sansom

    Campden BRI, Station Road, Chipping Campden, GL55 6LD, UK

    1 shared publication
  • Ayman El-Shibiny

    Biomedical Sciences, University of Science and Technology, Zewail City of Science and Technology Giza, Egypt

    1 shared publication
  • Benjamin K. Chan

    Department of Ecology and Evolutionary Biology, Yale University New Haven, CT, USA

    1 shared publication
  • Carmen Helena Coxon

    MHRA Science Campus, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK

    1 shared publication
  • Daniel De Vos

    Laboratory for Molecular and Cellular Technology, Burn Wound Center, Queen Astrid Military HospitalBrussels, Belgium; Faculty of Medicine, Catholic University of BukavuBukavu, Democratic Republic of Congo

    1 shared publication

Latest Publications

  • Open Access

    Phages for One Health: regulatory and product life cycle considerations

    by Liberty Duignan, Evelien M. Adriaenssens, Rosanna C. T. Wright, Annette Sansom, Ian MacLeod, Tobi E. Nagel, Joshua D. Jones, Joanne L. Fothergill, Carmen H. Coxon

    There is growing interest in bacteriophage (phage) technologies across the One Health spectrum. The UK Parliament’s Science, Technology and Innovation Select Committee recently published the results of its inquiry into ‘the antimicrobial potential of bacteriophages’ with recommendations on clarity on regulatory matters to support research and innovation. Products developed for different sectors will have different regulatory requirements. Here, we discuss how phage technology is applied across human, veterinary and food sectors, highlighting key regulatory considerations and the technical challenges that must be addressed to assure the quality, safety and efficacy of phage products. We also highlight the potential impact of phages in areas where they are most needed (low- and middle-income countries).

  • A Brief History of Phage Research and Teaching in Africa

    by Tobi E. Nagel, Ivy J. Mutai, Theodore Josephs, Martha R.J. Clokie


  • Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world

    by Tobi Nagel, Lillian Musila, Milkah Muthoni, Mikeljon Nikolich, Jesca L Nakavuma, Martha Rj Clokie


  • Open Access

    Development of a Lyophilization Process for Campylobacter Bacteriophage Storage and Transport

    by Lu Liang, Nicholas B. Carrigy, Samuel Kariuki, Peter Muturi, Robert Onsare, Tobi Nagel, Reinhard Vehring, Phillippa L. Connerton, Ian F. Connerton

    Bacteriophages are a sustainable alternative to control pathogenic bacteria in the post-antibiotic era. Despite promising reports, there are still obstacles to phage use, notably titer stability and transport-associated expenses for applications in food and agriculture. In this study, we have developed a lyophilization approach to maintain phage titers, ensure efficacy and reduce transport costs of Campylobacter bacteriophages. Lyophilization methods were adopted with various excipients to enhance stabilization in combination with packaging options for international transport. Lyophilization of Eucampyvirinae CP30A using tryptone formed a cake that limited processing titer reduction to 0.35 ± 0.09 log10 PFU mL−1. Transmission electron microscopy revealed the initial titer reduction was associated with capsid collapse of a subpopulation. Freeze-dried phages were generally stable under refrigerated vacuum conditions and showed no significant titer changes over 3 months incubation at 4 °C (p = 0.29). Reduced stability was observed for lyophilized phages that were incubated either at 30 °C under vacuum or at 4 °C at 70% or 90% relative humidity. Refrigerated international transport and rehydration of the cake resulted in a total phage titer reduction of 0.81 ± 0.44 log10 PFU mL−1. A significantly higher titer loss was observed for phages that were not refrigerated during transport (2.03 ± 0.32 log10 PFU mL−1). We propose that lyophilization offers a convenient method to preserve and transport Campylobacter phages, with minimal titer reduction after the drying process.


  • Open Access

    Delivering Phage Products to Combat Antibiotic Resistance in Developing Countries: Lessons Learned from the HIV/AIDS Epidemic in Africa

    by Tobi E. Nagel

    The antimicrobial resistance (AMR) crisis and HIV/AIDS epidemic exhibit many parallels. In both, infectious diseases have caused millions of deaths worldwide, with AMR expected to kill even more people each year than HIV/AIDS did at its peak. In addition, both have required or will require new classes of drugs for control. For HIV/AIDS, development of vital antiretroviral drugs (ARVs) was accomplished in several stages: expanding public awareness about the disease, gathering commitment from the international community to tackle the problem, and eventually establishing policies and global funds to deliver new therapeutics. For AMR, the pursuit of new antimicrobials appears to be following a similar trajectory. This paper examines how lessons and processes leading to ARVs might be applied to developing AMR drugs, in particular bacteriophages (phages). These possess many essential characteristics: inexpensive manufacture, rapid drug development, and a ready means to prevent phage-resistant microbes from emerging. However, the broad application of phage-based products has yet to be fully demonstrated, and will require both international coordination and modified regulatory policies.


  • Open Access

    The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria

    by Tobi E. Nagel, Benjamin K. Chan, Daniel De Vos, Ayman El-Shibiny, Erastus K. Kang'EThe, Angela Makumi, Jean-Paul Pirnay

    The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria